Valuation Takeda Pharmaceutical Company Limited

Stocks

4502

JP3463000004

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:30:00 2026-08-10 EDT			5-day change	1st Jan Change
5,582.00 ^JPY	+0.76%		+3.22%	+15.45%

08-05	Takeda Wins FDA Approval for First-in-Class Narcolepsy Treatment ORZEYFUL	MT
08-05	Takeda Receives U.S. Fda Approval for Orzeyful (Oveporexton) to Treat Narcolepsy Type 1	CI

Company Valuation: Takeda Pharmaceutical Company Limited

Data adjusted to current consolidation scope

Fiscal Period: March	2022	2023	2024	2025	2026	2027	2028	2029
Market Cap ¹	5,423,454	6,762,204	6,564,378	6,749,675	8,948,061	8,913,107	-	-
Change	-	24.68%	-2.93%	2.82%	32.57%	-0.39%	-	-
Enterprise Value (EV) ¹	8,919,170	10,611,015	10,950,330	10,725,175	5,130,461	12,836,969	12,628,538	12,300,116
Change	-	18.97%	3.2%	-2.06%	-52.16%	150.21%	-1.62%	-2.6%
P/E	23.8x	21.3x	45.4x	64.6x	46.4x	44.5x	27.7x	22.4x
PBR	0.95x	1.06x	0.9x	1x	1.2x	1.19x	1.18x	1.17x
PEG	-	0.5x	-0.8x	-2.5x	0.6x	15.48x	0.5x	0.9x
Capitalization / Revenue	1.52x	1.68x	1.54x	1.47x	1.99x	1.91x	1.88x	1.83x
EV / Revenue	2.5x	2.63x	2.57x	2.34x	1.14x	2.75x	2.66x	2.52x
EV / EBITDA	8.54x	9.19x	11.6x	9.71x	4.54x	9.54x	8.91x	8.26x
EV / EBIT	19.4x	21.6x	51.1x	31.3x	12.6x	28.8x	21x	17.4x
EV / FCF	8.92x	28.7x	43.4x	15.5x	8.14x	16.8x	16.6x	15.3x
FCF Yield	11.2%	3.49%	2.31%	6.43%	12.3%	5.96%	6.02%	6.55%
Dividend per Share ²	180	180	188	196	200	204.4	208.4	214.6
Rate of return	5.15%	4.14%	4.49%	4.44%	3.53%	3.66%	3.73%	3.84%
EPS ²	147.1	204.3	92.09	68.36	122	125.5	201.6	249.6
Distribution rate	122%	88.1%	204%	287%	164%	163%	103%	86%
Net sales ¹	3,569,006	4,027,478	4,263,762	4,581,600	4,505,700	4,670,831	4,749,405	4,873,975
EBITDA ¹	1,043,995	1,154,905	942,077	1,103,982	1,129,888	1,345,287	1,416,570	1,488,570
EBIT ¹	460,844	490,505	214,100	342,600	408,800	445,884	601,917	708,513
Net income ¹	230,059	317,017	144,067	107,900	191,800	192,092	317,615	383,553
Net Debt ¹	3,495,716	3,848,811	4,385,952	3,975,500	-3,817,600	3,923,862	3,715,431	3,387,009
Reference price ²	3,498.00	4,350.00	4,184.00	4,413.00	5,664.00	5,582.00	5,582.00	5,582.00
Nbr of stocks (in thousands)	1,550,444	1,554,530	1,568,924	1,529,498	1,579,813	1,596,759	-	-
Announcement Date	5/11/22	5/11/23	5/9/24	5/8/25	5/13/26	-	-	-

¹JPY in Million²JPY

Estimates

P/E, Detailed evolution

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
TAKEDA PHARMACEUTICAL COMPANY LIMITED	44.48x	2.75x	9.54x	3.66%	56.09B
ELI LILLY AND COMPANY	34.93x	12.78x	25.81x	0.56%	1,098B
JOHNSON & JOHNSON	29.12x	-	-	2.05%	631B
ABBVIE INC.	31.66x	7.38x	15.33x	2.77%	438B
ROCHE HOLDING AG	20.79x	4.93x	12.21x	2.68%	368B
NOVARTIS AG	22.24x	5.75x	14.34x	2.79%	298B
ASTRAZENECA PLC	20.77x	4.28x	12.16x	2.05%	251B
AMGEN INC.	26.18x	6.87x	12.22x	2.42%	226B
NOVO NORDISK A/S	13.88x	4.98x	10.54x	3.66%	209B
GILEAD SCIENCES, INC.	-41.32x	5.92x	33.42x	2.48%	165B
Average	20.27x	6.18x	16.18x	2.51%	374.04B
Weighted average by Cap.	25.29x	8.23x	18.62x	1.97%